Palbociclib in breast cancer neoadjuvant setting

Cyclin-dependent kinase 4/6 inhibitors represent a major advance in breast cancer treatment, emerging as the standard of care of the initial treatment of hormone receptor-positive and HER2-negative metastatic breast cancer. Their activity in this subset of patients leads to interest in their use in...

Descripción completa

Detalles Bibliográficos
Autores principales: Duarte, Sílvia Alexandra Cabral, de Azevedo, Daniela Silva Pádua, Sarmento, Teresa Tomé Ribeiro Malheiro, Sousa, Marta Verónica Velho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital Universitário da Universidade de São Paulo 2021
Materias:
Clinical Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387079/
https://www.ncbi.nlm.nih.gov/pubmed/34458177
http://dx.doi.org/10.4322/acr.2021.309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387079/
https://www.ncbi.nlm.nih.gov/pubmed/34458177
http://dx.doi.org/10.4322/acr.2021.309

Ejemplares similares